Läs upp

Cookies

Den här webbplatsen använder så kallade cookies. Cookies är små textfiler som lagras i din dator och sparar information om olika val som du gjort på en webbsida – t ex språk, version och statistik – för att du inte ska behöva göra dessa val en gång till. Tekniken är etablerad sedan många år tillbaka och används idag på väldigt många webbplatser på Internet.

Du kan när som helst ändra cookieinställningarna för denna webbplats.

FASS logotyp
Receptbelagd

Peka på symbolerna och beteckningarna till vänster för en förklaring.

Kontakt och länkar

Sök apotek med läkemedlet i lager

Sök lagerstatus

TAFINLAR

MiljöinformationReceptstatusFörmånsstatus
Novartis

Kapsel, hård 50 mg
(Ogenomskinliga, mörkt röda kapslar, längd cirka 18 mm, med "GS TEW" och "50 mg" tryckt på kapselns hölje.)

Cytostatiska/cytotoxiska medel, proteinkinashämmare

Aktiv substans:
ATC-kod: L01XE23
Läkemedel från Novartis omfattas av Läkemedelsförsäkringen.
  • Vad är miljöinformation?

Miljöpåverkan (Läs mer om miljöpåverkan)

Dabrafenib

Miljörisk: Användning av dabrafenib har bedömts medföra försumbar risk för miljöpåverkan.
Nedbrytning: Dabrafenib är potentiellt persistent.
Bioackumulering: Dabrafenib har låg potential att bioackumuleras.


Läs mer

Detaljerad miljöinformation

Detailed background information

Environmental Risk Classification


Predicted Environmental Concentration (PEC)


PEC is calculated according to the following formula:

PEC (μg/L) = (A*109*(100-R)/(365*P*V*D*100) = 1.5*10-6*A(100-R)

PEC = 0.0015 μg/L

Where:

A = 1 - 10 kg (market forecast range for API in Sweden year 2017, data from GSK Manufacturing Strategy). The upper range, 10kg, has been used in the PEC calculation.

R = 0% removal rate (conservatively, it has been assumed there is no loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation)

P = number of inhabitants in Sweden = 9 *106

V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (Reference 1)

D = factor for dilution of waste water by surface water flow = 10 (ECHA default) (Reference 1)


Predicted No Effect Concentration (PNEC)

Ecotoxicological studies


Green Algae (Pseudokirchneriella subcapitata):

IC50 96h (biomass) = 280 μg/L (OECD 201) (Reference 4)

NOEC = 220 μg/L


Water flea:

Acute toxicity

No data


Water flea (Daphnia magna):

Chronic toxicity

NOEC 21 days (reproduction) = 105 μg/L (OECD 211) (Reference 5)


Rainbow Trout:

Acute toxicity

No data


Fathead minnow (Pimephales promelas):

Chronic toxicity

NOEC 28 days (reproduction) = 1,740 μg/L (OECD 210) (Reference 6)


Other ecotoxicity data:

Chironomid (Chironomus riparius)

NOEC 28 days (reproduction) = 75,840 μg/kg (OECD 218) (Reference 7)


Microorganisms in activated sludge

EC50 3 hours (Inhibition) = 370,300 μg/L (OECD 209) (Reference 3)


PNEC = 105/10 = 10.50 μg/L


PNEC (μg/L) = lowest NOEC/10, where 10 is the assessment factor applied for three long-term NOECs. NOEC for water flea (= 105 ug/L) has been used for this calculation since it is the most sensitive of the three tested species.


Environmental risk classification (PEC/PNEC ratio)

PEC/PNEC = 0.0015/10.50 = 0.00014, i.e. PEC/PNEC ≤ 0.1 which justifies the phrase “Use of dabrafenib has been considered to result in insignificant environmental risk.”


Degradation

Biotic degradation


Ready degradability:

No data


Inherent degradability:

32% degradation in 28 days (OECD 301B) (Reference 8)

81% primary degradation in 28 days

This may be regarded as evidence for inherent primary biodegradation. This substance is not inherently biodegradable


Simulation studies:

Water-sediment study:

50% (DT50) degradation in 162-307 days (OECD 308) (Reference 9)

One significant Unknown WS-1 (> 10%) transformation product identified, C23H18O2N5F3S2. WS-1 was detected at 14% at day 59 but declined to 3% by the end of the study.


Non-extractable residue = 17.10% - 31.10%


Abiotic degradation

Hydrolysis:

No data


Photolysis:

No data


Justification of chosen degradation phrase:

Dabrafenib is not readily biodegradable nor inherently biodegradable. This substance is predicted to degrade in water sediment systems ≥ 120 days. However, non-extractable residues represent > 15% of the total material. The phrase “Dabrafenib is potentially persistent” is thus chosen.


Bioaccumulation

Bioconcentration factor (BCF):

Rainbow trout (Oncorhynchus mykiss)

BCF < 10 (OECD 305) (Reference 10)


Justification of chosen bioaccumulation phrase:

Since BCF < 500, the substance has low potential for bioaccumulation.


Excretion (metabolism)

The metabolism of dabrafenib is primarily mediated by CYP2C8 and CYP3A4 to form hydroxy-dabrafenib, which is further oxidized via CYP3A4 to form carboxy-dabrafenib. Carboxy-dabrafenib can be decarboxylated via a non-enzymatic process to form desmethyl-dabrafenib. Carboxy-dabrafenib is excreted in bile and urine. Desmethyl-dabrafenib may also be formed in the gut and reabsorbed. Desmethyl-dabrafenib is metabolized by CYP3A4 to oxidative metabolites. Hydroxy-dabrafenib terminal half-life parallels that of parent with a half-life of 10 hrs while the carboxy- and desmethyl-metabolites exhibited longer half-lives (21-22 hours). Mean metabolite to parent AUC ratios following repeat-dose administration were 0.9, 11 and 0.7 for hydroxy-, carboxy-, and desmethyl-dabrafenib, respectively. Based on exposure, relative potency, and pharmacokinetic properties, both hydroxy- and desmethyl-dabrafenib are likely to contribute to the clinical activity of dabrafenib; while the activity of carboxy-dabrafenib is not likely to be significant.


Terminal half-life following an intravenous single microdose is 2.6 hours. Dabrafenib terminal half-life after a single dose is 8 hours due to absorption-limited elimination after oral administration (flip-flop pharmacokinetics). IV plasma clearance is 12 L/hr. After an oral dose, the major route of elimination of dabrafenib is metabolism, mediated via CYP3A4 and CYP2C8. Dabrafenib related material is excreted primarily in faeces, with 71 % of an oral dose recovered in faeces and 23 % in urine as metabolites only. (Reference 2)


PBT/vPvB assessment

Dabrafenib does not fulfil the criteria for PBT and/or vBvP.


All three properties, i.e. ‘P’, ‘B’ and ‘T’ are required in order to classify a compound as PBT (Reference 1). Dabrafenib does not fulfil the criteria for PBT and/or vBvP based on a BCF < 500.


Please, also see Safety data sheets onhttp://www.msds-gsk.com/ExtMSDSlist.asp


References

  1. ECHA, European Chemicals Agency. 2008 Guidance on information requirements and chemical safety assessment.

  2. Pharmacokinetic properties: Metabolism and Elimination. Summary of Product Characteristics Tafinlar (Dabrafenib mesilate) 50mg and 75mg hard capsules. GlaxoSmithKline, March 2014.

  3. Graham R and Alderman D. GSK2118436B: Activated Sludge Respiration Inhibition Test (Carbon and Ammonium Oxidation). Report No.8236109. Covance Laboratories Limited, July 2011.

  4. Last G, Burke J, Flenely A and Jakes M. GSK2118436B: Inhibition of Growth to the Alga Pseudokirchneriella subcapitata. Report No. 8236106. Covance Laboratories Limited, April 2012.

  5. Last G, Burke J, Flenely A and Jakes M. GSK2118436B: Chronic effects to Daphnia magna. Report No. 8236107. Covance Laboratories Limited, April 2012.

  6. Last G, Burke J, Flenely A and Jakes M. GSK2118436B: Fish Early Life Stage Test (Pimephales promelas). Report No. 8236108. Covance Laboratories Limited, April 2012.

  7. Last G and Jakes M. GSK2118436B: Sediment-Water Chironomus riparius Toxicity Test using Spiked Sediment. Report No. 8250285. Covance Laboratories Limited, April 2012.

  8. Burwood C. GSK2118436B: Assessment of Inherent Biodegradability by Measurement of Carbon Dioxide Evolution with Specific Analysis. Report No. 8236103. Covance Laboratories Limited, May 2012.

  9. Fletcher T, Dixon K, Gilbert J. [14C]-GSK2118436B: Degradation in Water-Sediment Systems under Aerobic Conditions. Report No. 8236105. Covance Laboratories Limited, April 2012.

  10. Swales S. [14C]-GSK2118436B: Fish Bioconcentration Study. Report No. 8246812. Covance Laboratories Limited, April 2012.

Välj läkemedelstext
Hitta direkt i texten
Av